P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B)

• H. Lee,
• I. W. Flinn,
• J. Melear,
• R. Ramchandren,
• J. Friedman,
• J. M. Burke,
• Y. Linhares,
• M. Raval,
• R. Chintapatla,
• T. A. Feldman,
• H. Yimer,
• M. Islas-Ohlmayer,
• A. Dean,
• V. Rana,
• M. D. Gandhi,
• J. Renshaw,
• A. L. Gillespie-Twardy,
• L. Ho,
• M. Puhlmann,
• W. Guo,
• C. A. Yasenchak

Affiliations

H. Lee

1 MD Anderson, Houston

I. W. Flinn

2 Sarah Cannon Research Institute and Tennessee Oncology, Nashville

J. Melear

3 US Oncology Research, The Woodlands

R. Ramchandren

4 University of Tennessee Medical Center, Nashville

J. Friedman

5 University Hospitals Seidman Cancer Center, Cleveland

J. M. Burke

3 US Oncology Research, The Woodlands

Y. Linhares

6 US Oncology Research, Woodlands

M. Raval

3 US Oncology Research, The Woodlands

R. Chintapatla

7 Kadlec Clinic, Kennewick

T. A. Feldman

8 Lymphoma Division, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack

H. Yimer

3 US Oncology Research, The Woodlands

M. Islas-Ohlmayer

3 US Oncology Research, The Woodlands

A. Dean

3 US Oncology Research, The Woodlands

V. Rana

9 University of Colorado Health Hematology and Oncology, Colorado Springs

M. D. Gandhi

3 US Oncology Research, The Woodlands

J. Renshaw

3 US Oncology Research, The Woodlands

A. L. Gillespie-Twardy

3 US Oncology Research, The Woodlands

L. Ho

10 Seagen, Bothell

M. Puhlmann

10 Seagen, Bothell

W. Guo

10 Seagen, Bothell

C. A. Yasenchak

11 Willamette Valley Cancer Institute and Research Center, Eugene, United States of America